Barclays Decreases Exscientia PLC Price Target to $10.00
October 21, 2023
🌥️Trending News
Exscientia ($NASDAQ:EXAI) PLC is a leading AI-driven drug discovery company that uses artificial intelligence and machine learning to develop new medicines. Exscientia has made significant strides in the industry, having already developed multiple drugs in collaboration with major pharmaceutical companies such as GlaxoSmithKline and Sanofi. While the decrease in price may be a cause for concern for some investors, the long-term outlook for Exscientia remains strong as they continue to develop innovative AI-driven solutions that can help revolutionize the industry.
Price History
This news caused the stock to open at $5.2 and close at $5.0, a decrease of 2.5% from the previous closing price of $5.2. The decreased price target by Barclays indicates that the company’s performance may not be as strong as expected, and investors are not yet convinced of its success. Despite this, EXSCIENTIA PLC still remains a strong player in the pharmaceuticals and AI-driven drug discovery sector and may offer potential future growth for investors. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Exscientia Plc. More…
| Total Revenues | Net Income | Net Margin |
| 21.88 | -148.17 | -675.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Exscientia Plc. More…
| Operations | Investing | Financing |
| -172.74 | -80.89 | -2.56 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Exscientia Plc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 563.93 | 146.66 | 3.38 |
Key Ratios Snapshot
Some of the financial key ratios for Exscientia Plc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 44.1% | – | -788.6% |
| FCF Margin | ROE | ROA |
| -938.1% | -24.9% | -19.1% |
Analysis
At GoodWhale, we have conducted an in-depth examination of EXSCIENTIA PLC‘s wellbeing. After running through a series of tests and assessments on their financial standing, risk rating and other business aspects, we have concluded that EXSCIENTIA PLC is a low risk investment in terms of financial and business aspects. We encourage our users to become registered to gain access to our comprehensive review of EXSCIENTIA PLC which includes a detailed breakdown of the business and financial areas which may present potential risks. With the help of our assessment you can make an informed decision about whether EXSCIENTIA PLC is the right investment for you. More…
Peers
It is one of the leading artificial intelligence-driven drug discovery companies in the world and competes with IDEAYA Biosciences Inc, Navidea Biopharmaceuticals Inc, and Cogent Biosciences Inc. These companies are each engaged in research and development of drug discovery and development, using various technologies to bring new treatments to market.
– IDEAYA Biosciences Inc ($NASDAQ:IDYA)
IDEAYA Biosciences Inc is a biotechnology company that discovers and develops small molecule therapeutics for cancer and other genetically defined diseases. The company has a market cap of 830.92M as of 2023, making it one of the larger biotechnology companies in the industry. The company’s Return on Equity (ROE) is currently -10.66%, which suggests that there is an absence of profitability in the company’s operations. This could be a result of a lack of sales, mismanagement, or a combination of both. Nevertheless, the company has managed to remain competitive and maintain its large market cap despite its current negative ROE.
– Navidea Biopharmaceuticals Inc ($NYSEAM:NAVB)
Navidea Biopharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company has a market cap of 8.41M as of 2023, indicating its potential to grow in the near future. In addition, its Return on Equity (ROE) is 186.19%, implying that it is generating a considerable amount of income and effectively managing its resources. Navidea’s strong financial performance is indicative of its successful business strategy and its commitment to providing innovative diagnostic and therapeutic solutions to patients worldwide.
– Cogent Biosciences Inc ($NASDAQ:COGT)
Cogent Biosciences Inc is a biopharmaceutical company that develops and commercializes novel therapies for the treatment of a wide range of diseases. As of 2023, the company has a market cap of 873.67M and a Return on Equity of -26.61%. Cogent Biosciences’ market cap is indicative of its strong financial position, as it is able to generate a healthy amount of capital from its operations and investments. However, its negative Return on Equity indicates that the company has yet to generate a significant return on its investments.
Summary
Exscientia PLC is an automated drug development company that uses Artificial Intelligence (AI) to improve drug discovery. Despite this adjustment, analysts remain optimistic about the long term potential of Exscientia’s AI-driven platform and its ability to accelerate drug development. Going forward, investors should closely monitor Exscientia’s progress in clinical trials and partnerships with pharmaceutical companies, as further success in this area could significantly boost its share price. In addition, investors should monitor the company’s ability to attract new capital and build a strong portfolio of pharmaceutical partnerships.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
